Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
BCAX Bicara Therapeutics	$8.71 -1.1%	$12.06	$7.80 ▼ $28.09	$475.01M	N/A	598,644 shs	2.70 million shs
BCYC Bicycle Therapeutics	$7.24 -0.5%	$8.18	$6.10 ▼ $28.67	$501.40M	1.46	393,718 shs	209,672 shs
LXEO Lexeo Therapeutics	$4.12 -1.4%	$3.52	$1.45 ▼ $19.50	$136.77M	0.52	538,097 shs	959,826 shs
MGTX MeiraGTx	$6.61 -0.9%	$5.97	$3.85 ▼ $8.75	$531.21M	1.16	384,804 shs	928,477 shs

Options Trading Made Easy - Download Now

Learn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
BCAX Bicara Therapeutics	0.00%	-6.55%	-7.73%	-35.00%	+870,999,900.00%
BCYC Bicycle Therapeutics	0.00%	-2.43%	-16.78%	-19.29%	-64.18%
LXEO Lexeo Therapeutics	0.00%	+5.37%	+43.55%	+0.49%	-71.86%
MGTX MeiraGTx	0.00%	+4.26%	+23.32%	-9.82%	+57.01%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
BCAX Bicara Therapeutics	2.1533 of 5 stars	3.5	0.0	0.0	1.5	0.8	1.3
BCYC Bicycle Therapeutics	4.0883 of 5 stars	4.4	4.0	0.0	2.2	4.2	0.6
LXEO Lexeo Therapeutics	2.1185 of 5 stars	3.5	1.0	0.0	1.6	2.5	0.6
MGTX MeiraGTx	4.3909 of 5 stars	3.5	2.0	4.8	3.0	2.5	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
BCAX Bicara Therapeutics	3.00	Buy	$31.86	265.77% Upside
BCYC Bicycle Therapeutics	2.70	Moderate Buy	$25.00	245.30% Upside
LXEO Lexeo Therapeutics	3.00	Buy	$16.60	302.91% Upside
MGTX MeiraGTx	3.00	Buy	$24.00	263.09% Upside

Current Analyst Ratings Breakdown

Latest LXEO, BCYC, MGTX, and BCAX Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
5/30/2025	LXEO Lexeo Therapeutics	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Overweight ➝ Overweight	$16.00 ➝ $10.00
5/23/2025	BCAX Bicara Therapeutics	Wells Fargo & Company Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Underweight ➝ Equal Weight	$8.00
5/23/2025	BCAX Bicara Therapeutics	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform	$30.00
5/16/2025	BCAX Bicara Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$44.00 ➝ $41.00
5/16/2025	LXEO Lexeo Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$23.00 ➝ $15.00
5/14/2025	MGTX MeiraGTx	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$38.00 ➝ $35.00
5/13/2025	LXEO Lexeo Therapeutics	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$22.00 ➝ $20.00
5/5/2025	BCYC Bicycle Therapeutics	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Set Price Target	Equal Weight ➝ Equal Weight	$15.00 ➝ $17.00
5/2/2025	BCYC Bicycle Therapeutics	Royal Bank Of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Outperform ➝ Outperform	$35.00 ➝ $32.00
5/2/2025	BCYC Bicycle Therapeutics	B. Riley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Neutral ➝ Neutral	$17.00 ➝ $14.00
5/2/2025	BCYC Bicycle Therapeutics	JMP Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Market Outperform ➝ Market Outperform	$26.00 ➝ $22.00

(Data available from 6/29/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
BCAX Bicara Therapeutics	N/A	N/A	N/A	N/A	$9.04 per share	N/A
BCYC Bicycle Therapeutics	$35.28M	14.21	N/A	N/A	$11.48 per share	0.63
LXEO Lexeo Therapeutics	$650K	210.44	N/A	N/A	$3.53 per share	1.17
MGTX MeiraGTx	$33.28M	15.96	N/A	N/A	$0.87 per share	7.60

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
BCAX Bicara Therapeutics	-$68M	N/A	0.00	N/A	N/A	N/A	N/A	N/A	8/12/2025 (Estimated)
BCYC Bicycle Therapeutics	-$169.03M	-$3.14	N/A	N/A	N/A	-790.07%	-25.54%	-21.23%	8/5/2025 (Estimated)
LXEO Lexeo Therapeutics	-$98.33M	-$3.30	N/A	N/A	N/A	N/A	-85.86%	-68.48%	8/11/2025 (Estimated)
MGTX MeiraGTx	-$147.79M	-$2.32	N/A	17.39	N/A	-484.90%	-241.05%	-62.93%	8/11/2025 (Estimated)

Latest LXEO, BCYC, MGTX, and BCAX Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/13/2025	Q1 2025	BCAX Bicara Therapeutics	-$0.40	-$0.68	-$0.28	-$0.68	N/A	N/A
5/13/2025	Q1 2025	MGTX MeiraGTx	-$0.38	-$0.51	-$0.13	-$0.51	$4.44 million	$1.93 million
5/12/2025	Q1 2025	LXEO Lexeo Therapeutics	-$0.80	-$0.99	-$0.19	-$0.99	N/A	N/A
5/1/2025	Q1 2025	BCYC Bicycle Therapeutics	-$0.86	-$0.88	-$0.02	-$0.88	$8.67 million	$9.98 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
BCAX Bicara Therapeutics	N/A	N/A	N/A	N/A	N/A
BCYC Bicycle Therapeutics	N/A	N/A	N/A	N/A	N/A
LXEO Lexeo Therapeutics	N/A	N/A	N/A	N/A	N/A
MGTX MeiraGTx	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
BCAX Bicara Therapeutics	N/A	24.62	24.62
BCYC Bicycle Therapeutics	N/A	14.86	14.86
LXEO Lexeo Therapeutics	0.01	3.42	3.42
MGTX MeiraGTx	2.34	1.53	1.51

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
BCAX Bicara Therapeutics	N/A
BCYC Bicycle Therapeutics	86.15%
LXEO Lexeo Therapeutics	60.67%
MGTX MeiraGTx	67.48%

Insider Ownership

Company	Insider Ownership
BCAX Bicara Therapeutics	15.50%
BCYC Bicycle Therapeutics	22.90%
LXEO Lexeo Therapeutics	5.30%
MGTX MeiraGTx	7.50%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
BCAX Bicara Therapeutics	32	54.54 million	46.08 million	N/A
BCYC Bicycle Therapeutics	240	69.25 million	53.40 million	Optionable
LXEO Lexeo Therapeutics	58	33.20 million	31.44 million	Not Optionable
MGTX MeiraGTx	300	80.36 million	74.34 million	Optionable

LXEO, BCYC, MGTX, and BCAX Headlines

Recent News About These Companies

3 Promising Genomics Stocks to Keep an Eye On in 2025

June 27 at 9:06 AM | zacks.com

MeiraGTx Holdings plc (NASDAQ:MGTX) Shares Sold by Millennium Management LLC

June 11, 2025 | marketbeat.com

MeiraGTx (NASDAQ:MGTX) Trading Up 7.2% - Here's What Happened

June 10, 2025 | marketbeat.com

MeiraGTx (NASDAQ:MGTX) Shares Gap Up - Here's What Happened

June 9, 2025 | marketbeat.com

Short Interest in MeiraGTx Holdings plc (NASDAQ:MGTX) Increases By 16.9%

June 5, 2025 | marketbeat.com

Nuveen Asset Management LLC Boosts Stock Holdings in MeiraGTx Holdings plc (NASDAQ:MGTX)

June 5, 2025 | marketbeat.com

MeiraGTx Announces the Presentation of Four Posters at the American Society of Gene and Cell Therapy (ASGCT) 2025 Annual Meeting

May 13, 2025 | globenewswire.com

MeiraGTx Holdings PLC (MGTX) Reports Q1 Loss, Misses Revenue Estimates

May 13, 2025 | zacks.com

MeiraGTx Reports First Quarter 2025 Financial and Operational Results

May 13, 2025 | globenewswire.com

FDA grants RMAT status to MeiraGTx’s Parkinson’s treatment

May 10, 2025 | investing.com

MeiraGTx Granted FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for AAV-GAD for the Treatment of Parkinson’s Disease

May 9, 2025 | finance.yahoo.com

MeiraGTx Granted FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for AAV-GAD for the Treatment of Parkinson's Disease

May 9, 2025 | globenewswire.com

Cone Rod Dystrophy Market Report 2025-2030, with Profiles of SparingVision, Beacon Therapeutics, Nanoscope Therapeutics, MeiraGTx, Ascidian Therapeutics, jCyte, BlueRock Therapeutics and more

April 29, 2025 | globenewswire.com

Richard Giroux Sells 24,000 Shares of MeiraGTx Holdings plc (NASDAQ:MGTX) Stock

April 23, 2025 | insidertrades.com

Insider Selling: MeiraGTx Holdings plc (NASDAQ:MGTX) CEO Sells 47,500 Shares of Stock

April 9, 2025 | insidertrades.com

MeiraGTx Holdings: Gaining Regulatory Focus

March 25, 2025 | seekingalpha.com

MeiraGTx Holdings plc (NASDAQ:MGTX) Is Expected To Breakeven In The Near Future

March 24, 2025 | finance.yahoo.com

MeiraGTx Holdings (MGTX) Partners with Hologen for $200M AI-Powered Parkinson’s Treatment

March 18, 2025 | msn.com

MeiraGTx price target raised to $13 from $11 at RBC Capital

March 17, 2025 | markets.businessinsider.com

Meiragtx Holdings (MGTX) Gets a Buy from Evercore ISI

March 17, 2025 | markets.businessinsider.com

MEIRAGTX HOLDINGS Earnings Results: $MGTX Reports Quarterly Earnings

March 15, 2025 | nasdaq.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

LXEO, BCYC, MGTX, and BCAX Company Descriptions

Bicara Therapeutics NASDAQ:BCAX

$8.71 -0.10 (-1.14%)

Closing price 06/27/2025 04:00 PM Eastern

Extended Trading

$8.75 +0.04 (+0.46%)

As of 06/27/2025 07:47 PM Eastern

Bicara Therapeutics Inc., a clinical-stage biopharmaceutical company, develops bifunctional therapies for solid tumors. Its lead program is ficerafusp alfa, a bifunctional antibody that combines an epidermal growth factor receptor (EGFR) directed monoclonal antibody with a domain that binds to human transforming growth factor beta (TGF-b) for the treatment of solid tumors. The company was incorporated in 2018 and is based in Boston, Massachusetts.

Bicycle Therapeutics NASDAQ:BCYC

$7.24 -0.04 (-0.55%)

Closing price 06/27/2025 04:00 PM Eastern

Extended Trading

$7.25 +0.01 (+0.12%)

As of 06/27/2025 04:49 PM Eastern

Bicycle Therapeutics plc, a clinical-stage biopharmaceutical company, develops a class of medicines for diseases that are underserved by existing therapeutics in the United States and the United Kingdom. Its product pipeline comprising BT8009, a bicycle toxin conjugate (BTC) which is in phase I/II/III clinical trial for the treatment of high nectin-4 expressing tumors; BT5528, a BTC which is in phase I/II clinical trial for the treatment of Ephrin type A receptor 2 expressing tumor; BT7480, a Bicycle TICA molecule which is in phase I/II targeting Nectin-4 and agonizing CD137; and BT7455, a Bicycle TICA molecule targeting Ephrin type A receptor 2 and CD137 and is in preclinical trial. The company also developing BT1718, a bicycle toxin conjugate (BTC), which is in Phase I/IIa clinical trials targeting tumors that express Membrane Type 1 matrix metalloprotease; and BT7401, a multivalent bicycle CD137 agonist which is in phase IIa to treat advanced solid tumors. In addition, it develops Novel anti-infective, which is in preclinical trial targeting anti-infectives disease; CNS targets, which is in preclinical trial targeting CNS disease; and Novel neuromuscular targets, which is in preclinical trial targeting neuromuscular disease. Further, the company collaborates with biopharmaceutical companies and organizations to develop programs in therapeutic areas. It has collaboration and license agreement with Bayer Consumer Care AG; Novartis Pharma AG; Cancer Research UK; Cancer Research Technology Ltd; and Oxurion NV. Bicycle Therapeutics plc was incorporated in 2009 and is headquartered in Cambridge, the United Kingdom.

Lexeo Therapeutics NASDAQ:LXEO

$4.12 -0.06 (-1.44%)

Closing price 06/27/2025 04:00 PM Eastern

Extended Trading

$4.12 +0.00 (+0.12%)

As of 06/27/2025 04:34 PM Eastern

Lexeo Therapeutics, Inc. operates as a clinical stage genetic medicine company that focuses on hereditary and acquired diseases. The company develops LX2006, which is an AAVrh10-based gene therapy candidate for the treatment of Friedreich's ataxia (FA) cardiomyopathy; LX2020, an AAVrh10-based gene therapy candidate for the treatment of plakophilin-2 arrhythmogenic cardiomyopathy; LX2021, a gene therapy candidate for the treatment of DSP cardiomyopathy associated with it; and LX2022, a gene therapy candidate for the treatment of hypertrophic cardiomyopathy, or HCM caused by TNNI3 gene. It also develops LX1001, an AAVrh10-based gene therapy candidate for the treatment of APOE4 homozygous; LX1020, a gene therapy candidate for the treatment of APOE4 homozygous; LX1021 for the treatment of APOE4 homozygotes; and LX1004 for the treatment of CLN2 Batten disease. The company was incorporated in 2017 and is based in New York, New York.

MeiraGTx NASDAQ:MGTX

$6.61 -0.06 (-0.90%)

Closing price 06/27/2025 04:00 PM Eastern

Extended Trading

$6.61 0.00 (0.00%)

As of 06/27/2025 05:59 PM Eastern

MeiraGTx Holdings plc, a clinical stage gene therapy company, focusing on developing treatments for patients with serious diseases. The company develops various therapies for ocular diseases, including inherited retinal diseases and large degenerative ocular diseases, neurodegenerative diseases, and xerostomia. Its programs in clinical development include Phase I/II clinical stage programs in achromatopsia, X-linked retinitis pigmentosa, and RPE65-deficiency; Phase I clinical trials for radiation-induced xerostomia; and Parkinson's program that has completed a Phase II trial. It has a research collaboration agreement with Janssen Pharmaceuticals, Inc. for the research, development, and commercialization of gene therapies for the treatment of inherited retinal disease. The company was incorporated in 2015 and is based in New York, New York.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time